Showing 391-400 of 447 results for "".
- LaserCap Receives 510(k) Clearance for Hair Treatment Devicehttps://practicaldermatology.com/news/lasercap-receives-510k-clearance-for-hair-treatment-device/2458894/LaserCap® Company has received FDA 510(k) clearance for the
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting System Scores FDA 510(k) clearancehttps://practicaldermatology.com/news/bimini-health-techs-dermapose-access-office-based-fat-harvesting-system-scores-fda-510k-clearance/2460368/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access sy
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to
- FDA Grants 510(k) Clearance to Chemence Medical’s Exofin Fusion Redesignhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-chemence-medicals-exofin-fusion-redesign/2460736/The U.S. Federal Drug Administration gave its nod to Chemence Medical’s redesigned exofin fusion skin closure system. Exofin fusion combines a self-adhering flexible mesh strip and a fast-curing 2-octyl cyanoacrylate topical adhesive to close and seal incisions while forming an im
- US FDA Issues Draft Updated Recommendations on Submitting a New 510(k) for Device Modificationshttps://practicaldermatology.com/news/us-fda-issues-draft-of-updated-recommendations-on-submitting-a-new-510k-for-device-modifications/2458471/The U.S. Food and Drug Administration (FDA) issued draft updated recommendations to help manufacturers determine when they are required to notify the FDA about modifications made
- Sculpsure Cleared to Treat Double Chinshttps://practicaldermatology.com/news/sculpsure-cleared-to-treat-double-chins/2458036/Cynosure's SculpSure® is now cleared for submental fat reduction. The U.S. Food and Drug Administration (FDA) granted an expanded FDA 510(k) clearance for this area, Hologic, Inc. reports.
- Novartis receives FDA regular approval for Tafinlar + Mekinist for Melanomahttps://practicaldermatology.com/news/novartis-receives-fda-regular-approval-for-tafinlar-mekinist-for-melanoma/2458804/The FDA granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) from Novartis for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. This is th
- Risk-Guided Screening Enhances Early Skin Cancer ID in Transplant Cohorthttps://practicaldermatology.com/news/risk-guided-screening-enhances-early-skin-cancer-id-in-transplant-cohort/2483972/A risk-based skin cancer surveillance strategy was associated with improved early detection rates among solid organ transplant (SOT) recipients, according to findings from a recent retrospective cohort analysis of the implementation of the KP-SUNTRAC program across K